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RESEARCH ARTICLE
Neuroplasticity pathways 
and protein-interaction networks are 
modulated by vortioxetine in rodents
Jessica A. Waller1, Sara Holm Nygaard2, Yan Li1, Kristian Gaarn du Jardin3, Joseph A. Tamm4, 
Aicha Abdourahman4, Betina Elfving3, Alan L. Pehrson1, Connie Sánchez1* and Rasmus Wernersson2,5*
Abstract 
Background: The identification of biomarkers that predict susceptibility to major depressive disorder and treatment 
response to antidepressants is a major challenge. Vortioxetine is a novel multimodal antidepressant that possesses 
pro-cognitive properties and differentiates from other conventional antidepressants on various cognitive and plastic-
ity measures. The aim of the present study was to identify biological systems rather than single biomarkers that may 
underlie vortioxetine’s treatment effects.
Results: We show that the biological systems regulated by vortioxetine are overlapping between mouse and rat 
in response to distinct treatment regimens and in different brain regions. Furthermore, analysis of complexes of 
physically-interacting proteins reveal that biomarkers involved in transcriptional regulation, neurodevelopment, neu-
roplasticity, and endocytosis are modulated by vortioxetine. A subsequent qPCR study examining the expression of 
targets in the protein–protein interactome space in response to chronic vortioxetine treatment over a range of doses 
provides further biological validation that vortioxetine engages neuroplasticity networks. Thus, the same biology is 
regulated in different species and sexes, different brain regions, and in response to distinct routes of administration 
and regimens.
Conclusions: A recurring theme, based on the present study as well as previous findings, is that networks related to 
synaptic plasticity, synaptic transmission, signal transduction, and neurodevelopment are modulated in response to 
vortioxetine treatment. Regulation of these signaling pathways by vortioxetine may underlie vortioxetine’s cognitive-
enhancing properties.
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Background
A significant challenge in major depressive disorder 
(MDD) is to identify biomarkers that diagnose the dis-
ease and predict treatment response. However, the het-
erogeneous nature of MDD makes it difficult to assign a 
single biomarker for these purposes. An emerging con-
cept is that MDD may not be attributed to single genes 
but rather to deficits in signaling at the synapse and 
circuit levels, which may be reversed with antidepres-
sant treatment. This evolving idea is the basis for the 
synaptogenic or excitatory synapse hypothesis of depres-
sion with a focus on specifically promoting cortical and 
hippocampal activation [1–4]. Several lines of evidence 
provide support for this idea. Postmortem studies in 
the prefrontal cortex of MDD patients reveal decreases 
in spine synapse density and reduced expression of 
synaptic genes, including those coding for α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
subunits and neurotransmitter release machinery [5, 
6]. Transcriptional repression of these genetic compo-
nents is correlated with decreased dendritic complexity 
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and depressive-like behaviors [5]. In a chronic restraint 
stress model of depression, glutamatergic transmission 
is impaired in conjunction with decreased AMPA and 
N-methyl-d-aspartate (NMDA) receptor surface expres-
sion [7]. Elevation of serotonin (5-HT) levels by antide-
pressant treatment can modulate glutamatergic signaling 
[8]. Accordingly, 5-HT signaling via 5-HT1B receptors 
leads to potentiation of excitatory postsynaptic potentials 
at hippocampal synapses and increased phospho-AMPA 
receptor subunit levels [9].
Vortioxetine is a multimodal-acting antidepressant 
with a cognitive-enhancing profile. In addition to acting 
as a 5-HT transporter (SERT) inhibitor, it is an antago-
nist at 5-HT1D, 5-HT3, and 5-HT7 receptors, agonist at 
5-HT1A receptors, and partial agonist at 5-HT1B receptors 
[10, 11]. The localization of the vortioxetine 5-HT recep-
tor targets on glutamatergic and GABAergic neurons 
permits modulation of glutamatergic neurotransmission 
by 5-HT [8]. In support of this, vortioxetine enhances 
cortical pyramidal neuron activity [12] and augments 
theta-burst long-term potentiation (LTP), which may 
underlie synaptic plasticity [13]. In contrast, the selective 
serotonin-reuptake inhibitor (SSRI) escitalopram failed 
to potentiate pyramidal neuron firing [12] and LTP [13]. 
In addition, vortioxetine promotes dendritic branching 
[14], increases dendritic spine density in  vivo [15], and 
induces spine and synapse remodeling in vitro [16], indi-
cating a role for vortioxetine in morphological plasticity. 
In contrast, the SSRI fluoxetine had no effect on dendritic 
branching and spine density at earlier timepoints [14, 15] 
and failed to induce changes in spine morphology in vitro 
[16]. At the behavioral level, vortioxetine enhances cog-
nitive performance in paradigms of recognition, spatial, 
and fear memory, and executive functioning [17–21]. In 
5-HT-depleted rats, vortioxetine, but not escitalopram or 
duloxetine, reversed deficits in the hippocampal-depend-
ent novel object recognition task [17] and in the Y-maze 
spontaneous alternation spatial memory task [21]. In 
middle-aged mice, a model of cognitive decline comorbid 
with depression, vortioxetine, but not fluoxetine, restored 
visuospatial impairments in the object placement test 
[20].
In line with these effects of vortioxetine on plasticity 
and cognitive performance, current studies reveal vorti-
oxetine regulates neuroplasticity gene expression in the 
cortex and hippocampus, brain regions linked to cogni-
tive dysfunction in depression [22, 23]. An acute study in 
adult naïve rats revealed increases in mRNA expression 
of genes related to serotonergic and glutamatergic signal-
ing, protein synthesis, and dendritic spine dynamics fol-
lowing vortioxetine, but not fluoxetine, administration 
in the frontal cortex [24]. Likewise, a chronic vortiox-
etine study in 12-month-old mice demonstrated elevated 
mRNA levels of genes related to transcription, signal 
transduction, plasticity, dendritic spine remodeling, and 
neurotransmitter release in the hippocampus, similar to 
those levels found in young, 3-month-old, vehicle-treated 
mice [20]. In contrast, fluoxetine failed to increase mRNA 
expression of the majority of plasticity markers examined 
[20].
The purpose of the present study was to perform a 
retrospective cross-species network analysis to deter-
mine whether shared biological systems rather than sin-
gle biomarkers are regulated in response to vortioxetine 
treatment. We explored whether common underlying 
biological mechanisms can be linked from distinct vor-
tioxetine studies [20, 24]. A protein–protein interaction 
analysis is a stringent and effective method to uncover 
shared networks. We hypothesized that common net-
works (biological systems of interacting proteins) are 
engaged in rodent models in response to various vorti-
oxetine treatment regimens. The network analysis was 
performed with qPCR data for selected sets of biomark-
ers in two distinct models (with little overlap in the two 
biomarker sets), and thus full-scale overrepresentation 
analyses were not possible. The limited nature of the 
qPCR datasets inevitably introduces a bias to the study 
and forces limitations to which parts of the protein inter-
actome can be queried for regulated networks. With the 
lack of global data, we therefore employed alternative 
approaches to discover the protein interaction networks, 
including the investigated biomarkers that might drive 
the response to vortioxetine in two distinct animal mod-
els differing in species, sexes, brain regions, and treat-
ment regimens.
Methods
Animals
All animal procedures were in accordance with Lundbeck 
Research U.S.A. Institutional Animal Care and Use Com-
mittee and NIH federal guidelines. Adult male Sprague–
Dawley rats (8–12  weeks) and middle-aged female 
C57BL/6 mice (11 months) were obtained from Charles 
River (Wilmington, MA, USA) and were kept in a 12:12 
light:dark cycle with ad libitum access to food and water.
Dosing and RNA isolation
A summary of studies and experimental paradigms is 
shown in Table 1. For acute studies, adult male Sprague–
Dawley rats received vehicle or vortioxetine (generated 
by H. Lundbeck A/S, Valby, Denmark) (10  mg/kg, i.p.), 
a clinically-relevant dose corresponding to full rSERT 
occupancy and ~80% occupancy at the r5-HT1B recep-
tor, at 2, 8, 12, or 27 h prior to harvesting the frontal cor-
tex. RNA purification, cDNA synthesis, and quantitative 
real-time polymerase chain reaction (qPCR) using SYBR 
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green were carried out as described elsewhere [24, 25]. 
Transcript levels of 80 genes involved in serotonergic and 
glutamatergic neurotransmission as well as neuroplasti-
city were assessed.
For chronic studies in mouse, aged female C57BL mice 
received 1 month treatment of vehicle or vortioxetine (H. 
Lundbeck A/S) (0.6  g base per kg food) in Purina 5001 
rodent chow (Research Diets Inc., New Brunswick, NJ), 
a clinically-relevant dose that fully occupies the mSERT 
in addition to ~50% occupancy at the m5-HT1B receptor 
[20]. mRNA levels of several neuroplasticity genes were 
measured in the hippocampus using qPCR as previously 
described [20].
For subsequent chronic vortioxetine studies to vali-
date the network analysis, adult male Sprague–Dawley 
rats, n = 12/group, received 0.22 g/kg of vortioxetine (H. 
Lundbeck A/S) food (Research Diets Inc.) (correspond-
ing to ~50% rSERT occupancy), 0.6  g/kg vortioxetine 
food (Research Diets Inc.) (corresponding to full rSERT 
occupancy and ~50% occupancy at r5-HT1B), or 1.8  g/
kg vortioxetine food (Research Diets Inc.) (achieving full 
occupancy at rSERT and ~90% occupancy at r5-HT1B) 
for 1 month (also see [28]). Gene expression was assessed 
in the frontal cortex and hippocampus.
Cortex and hippocampus were rapidly dissected and 
stored in RNAlater (Ambion; Life Technologies, Carls-
bad, CA, USA) at −20  °C prior to processing. Tissue 
was homogenized on ice in 1 ml of lysis buffer (Ambion 
RNAqueous 96 kit) using an Autogizer (Tomtec, Ham-
den, CT, USA). Total RNA was extracted from an aliquot 
of the lysate using the Ambion RNAqueous 96 automated 
kit according to the manufacturer’s protocol. Following 
RNA elution from the column, a second DNase diges-
tion was added to eliminate any residual genomic DNA 
in the samples. The total RNA was evaluated with an 
Agilent Bioanalyzer 2100 to determine RNA concentra-
tion and integrity. The average RNA integrity number 
(RIN) values were 6.7 for the cortex and 6.3 for the hip-
pocampus. RNA concentration was normalized to 20 ng/
µl and reverse transcription was performed using 200 ng 
of RNA and Superscript VILO (Life Technologies, Carls-
bad, CA, USA) according to the manufacturer’s protocol. 
The Quant-It dye intercalation assay (Life Technologies, 
Carlsbad, CA, USA) was used to determine cDNA yield, 
and the samples were normalized to a concentration of 
3 ng/µl. mRNA levels of various plasticity-related genes 
and receptors were examined by OpenArray qPCR, 
described below.
Network and protein–protein interaction analysis
Gene expression analysis and integrative modeling for net-
work identification were performed by Intomics A/S (Lyn-
gby, Denmark). The main source of network data used in 
the analysis was the experimentally derived physical pro-
tein–protein interaction database InWeb_IM [26]. Briefly, 
InWeb_IM is a large, robust, high confidence database of 
inferred human physical protein–protein interactions gath-
ered from multiple databases of experimental evidence. 
For a full description of the resource including background 
databases and scoring algorithms, please refer to [26]. This 
database has been shown to have a very high coverage of 
interaction data for brain-regulated genes, suggesting it to 
be particularly useful for discovery of new pathway rela-
tionships in neuropsychiatric diseases [26]. Two different 
types of protein-interaction networks were derived from 
the InWeb_IM database (February 2014 version):
1. Networks comprised of transcriptionally-regulated 
proteins and their interaction partners.
2. Pre-defined protein interaction networks from the 
Intomics in-house protein Complex Catalogue of 2412 
topological clusters found in the full network space, 
built to facilitate analyses based on fixed networks. The 
complex catalog was generated by considering all 1st 
order networks around receptors and signaling path-
way-related proteins annotated in UniProt and KeGG, 
pruning the networks for “sticky proteins” (proteins 
with a high number of interactions outside the current 
network), and then merging all networks with a high 
degree of overlap (>95%).
Table 1 Summary of studies and experimental paradigms
Outline of experimental conditions for mouse and rat studies used in the network analysis and for the OpenArray qPCR study for biological validation of the network 
analysis. See references for additional details regarding these studies including animal models and differentiation to other antidepressants
Study Species Sex Age (weeks) Dosing Regi‑
men
Brain Regions Figure(s) References
Network analysis Mouse Female 48 Chronic Hippocampus Figures 2, 3, 4, 5 and Addi-
tional file 1: Table S1
Li et al. [20]
Network analysis Rat Male 8 Acute Frontal cortex Figures 2, 3, 4, 5 and Addi-
tional file 1: Table S2
du Jardin et al. [24]
OpenArray qPCR Rat Male 12 Chronic Frontal cortex, Hippocam-
pus
Figure 6 Waller-et al. [27]
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The protein interaction networks can be described as 
draft pathways as they are typically not as well-described 
as literature-derived canonical pathways. They however 
hold a valuable potential for discovery of new insight, as 
the use of protein–protein interaction data allows for an 
analysis that goes beyond what is currently annotated in 
literature-derived pathways.
To facilitate the network analysis, mouse and rat genes 
were mapped to human orthologs using the multiple 
orthology database approach outlined in [26], to ensure 
correct mapping in cases of uncertainty, and qPCR val-
ues were  log2 transformed. Subsequently, quality control 
plots of the  log2-transformed values were generated to 
identify outliers. The Mann–Whitney U test was used 
to calculate p values, which were then adjusted using the 
Benjamini–Hochberg procedure for correction for multi-
ple testing.
The following approaches were used for identification 
of networks significantly associated with the gene expres-
sion data (see Fig. 1 for an overview of the workflow):
1. Genes found to be significantly regulated in the gene 
expression analysis were used to seed a “virtual pull-
down” in the full experimentally-derived, protein–pro-
tein interaction database: Other proteins directly inter-
acting with the protein products of the regulated genes 
Fig. 1 Schematic of procedure for network analysis based on differentially-regulated targets. Work-flow for generating protein networks. Follow-
ing mapping of targets to human orthologues and differential expression analysis of qPCR data, significantly-regulated targets were used to build 
networks of protein–protein interactions
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were found and added to the network based on their 
degree of interconnectivity, and interactions between 
those proteins were reported as well. Since these pro-
tein interaction clusters from the human interactome 
are based on experimental data and encompass a large 
range of proteins, this approach has the potential to 
extract new information about the underlying biology 
affected by transcriptional regulation.
2. The p values from all tested genes were mapped 
onto the corresponding proteins in the Complex 
Catalogue, and for each network, a combined score 
was calculated using Fisher’s combined probabil-
ity test. The 839 networks that contained any of the 
measured biomarkers were ranked according to this 
combined score, and the best scoring networks were 
investigated.
OpenArray qPCR platform
OpenArray qPCR was performed as described previ-
ously [20, 27]. Briefly, pre-amplification of the samples was 
accomplished using 12 cycles of PCR in a reaction con-
taining 10 ng of cDNA, 112 primer sets exactly matching 
targets on the OpenArray chip, and 2× Taqman Preamp 
master mix (Life Technologies, Carlsbad, CA, USA) accord-
ing to the vendor’s protocol. A complete list of targets 
tested can be found in Additional file 1: Table S3. Ampli-
fied samples were analyzed on a QuantStudio 12K flex 
instrument (Life Technologies, Carlsbad, CA, USA). Data 
analysis was performed using the Expression Suite software 
package provided with the instrumentation. Global nor-
malization across the entire chip was used to adjust the raw 
expression values for all targets. More specifically, within 
each sample, the geometric mean of the comparative cycle 
threshold (Ct) values for all of the qPCR assays was calcu-
lated. Using this value, a delta Ct was calculated for every 
assay in each sample (geometric mean for sample X minus 
the Ct for assay 1, assay 2, etc., across the sample). These 
delta Ct values were then used to calculate expression levels 
in the control and different treatment groups, which then 
enabled differential expression levels to be determined. The 
reported relative expression (RQ) value represents the ratio 
of normalized expression in each treatment group divided 
by the normalized expression in the control group. Val-
ues are denoted as mean ± SEM. Statistical significance is 
defined as a false discovery rate (FDR) p value of p < 0.05.
Results
Network analysis reveals common biological systems 
related to plasticity and development are modulated 
in response to vortioxetine in mouse and rat
Previous qPCR studies examining expression of various 
neuroplasticity-related genes in adult rats treated with 
acute vortioxetine and middle-aged mice treated with 
chronic vortioxetine revealed upregulation of various 
signal transduction, plasticity, and neurotransmission-
related genes [20, 24]. We sought to determine whether 
there is overlap and common biological networks regu-
lated in response to vortioxetine, as variation is typically 
evident at the network level and there was little overlap 
in the markers examined in these two qPCR studies. Fol-
lowing comprehensive mapping to orthologous human 
proteins and differential expression analysis, including 
correction for multiple testing (Additional file  1: Tables 
S1 and S2), differentially-regulated targets were used to 
generate networks, as described above. Comparisons 
between vehicle and vortioxetine treatments in middle-
aged mice (n = 10 animals for vehicle and vortioxetine) 
and adult rat samples (n  =  5 animals for vehicle, and 
n = 6 animals for vortioxetine) were used for the differen-
tial expression analysis. Following corrections for multi-
ple testing, 5 mouse genes related to plasticity, Arc, Fmr1, 
Ndor1, Shank1, and Slc6a3, were significantly regulated 
(adjusted p value of <0.05 (Table 2). There were no signif-
icant genes after the rat targets were corrected for mul-
tiple testing, most likely due to the lower n values in the 
rat study. Thus, the differentially-regulated targets before 
correction were used for the network analysis. A total of 
14 plasticity-related genes including, Cacng2, Cacng6, 
Cacng8, Grik4, Grik5, Grm1, Grm5, Grm7, Homer3, 
Htr1b, Mtor, Ppp1r9b, Prkca, and Syn3, were significantly 
upregulated following differential analysis (Table 3).
Subsequently, these differentially-regulated genes were 
used as seeds to query the InWeb_IM database of inter-
acting proteins, and the 1st order protein–protein net-
works shown in Fig.  2 were identified. The mouse and 
rat networks only had two proteins in common (Homer 
protein homolog 1 and Homer protein homolog 3), but 
overlaying the networks revealed that the other protein 
members of the two networks were interconnected. Fur-
thermore, merging the two networks yielded a single net-
work capable of explaining the transcriptional response 
in both model organisms (Fig.  3). This biological net-
work of 109 proteins contained clusters of interacting 
Table 2 Biomarkers significantly upregulated by  vortiox-
etine in mouse hippocampus (Old VEH vs. Old VOR)
Significance is determined relative to vehicle (VEH) treatment (n = 10 animals 
per group). Following correction for multiple testing, 5 genes were significantly 
upregulated and used as inputs for the subsequent network analysis
a Benjamini–Hochberg correction for multiple testing
Gene name Protein ID BHa corrected p value
Arc ARC 0.0174
Fmr1 FMR1 0.0217
Ndor1 NDOR1 0.0174
Shank1 SHANK1 0.0217
Slc6a3 SC6A3 0.0174
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proteins related to neuronal development, including 
Notch signaling and neuron formation and outgrowth, 
synaptic transmission, receptor and mTOR signaling, 
synaptic plasticity, metabolism, and cell growth and 
apoptosis, and was significantly engaged in both mouse 
and rat (Additional file  2: Figure S1). For each protein 
in the network, membership of Reactome pathways was 
established using the official Reactome mapping file 
(UniProt2Reactome.txt, downloaded from www.reac-
tome.org, December 21, 2016). The mapping file was 
processed to only include reviewed human proteins from 
UniProt and protein-pathway associations with the evi-
dence code “traceable author statement” (TAS). The most 
prevalent Reactome pathways with respect to overlap in 
proteins with the merged mouse and rat network were 
Interactions of neurexins and neuroligins at synapses, 
Activation of Ca2+-permeable Kainate receptors, mTOR 
signaling, and Cargo recognition for clathrin-mediated 
endocytosis. The protein overlap with these pathways is 
shown in Fig.  4. Applying the Wilcoxon rank sum test 
to mouse and rat data, respectively, revealed that p val-
ues for differential expression were significantly lower 
for biomarkers within the network than for other tested 
biomarkers in both species [mouse: Wilcoxon rank sum 
test p  =  0.0000808 for enrichment of low p values for 
biomarkers in the network (n  =  19) compared to the 
remaining measured biomarkers (n = 53); rat: Wilcoxon 
rank sum test p =  0.00000217 for enrichment of low p 
values for biomarkers in the network (n = 28) compared 
to the remaining measured biomarkers (n = 52)], indicat-
ing a shared biology in response to vortioxetine in two 
distinct model systems examining a different set of bio-
markers. Even with the low number of genes examined 
in both datasets, meaningful biological data could be 
extracted using this method to elucidate potential molec-
ular mechanisms underlying vortioxetine treatment.
Protein complex analysis confirms neuroplasticity 
and development‑related biomarkers are regulated 
by vortioxetine in mouse and rat
Ranking the fixed protein–protein interaction networks 
(draft pathways) from the Complex Catalogue of topo-
logical clusters of physically-interacting proteins based 
on their regulation in the qPCR data led to the identi-
fication of networks significantly associated with the 
vortioxetine response (Fig.  5). Gene ontology overrep-
resentation analyses performed with a custom imple-
mentation of the GeneMerge algorithm [28] and the 
Gene Ontology Consortium GoSlim annotations (acces-
sion date May 14, 2014) revealed biological functions 
in the networks related to common themes of synaptic 
plasticity, transmission, and neurodevelopment. These 
networks included the neuronal activity marker ARC 
(Fig.  5a), transcriptional regulator FOS (Fig.  5b), EPN1 
(Epsin 1), associated with endocytosis and actin remod-
eling (Fig. 5c), and SEMA4G (Semaphorin 4g), related to 
neurodevelopment and plasticity (Fig. 5d).
qPCR analysis provides biological validation of targets 
identified in the network analysis
The discovery of additional markers in the protein inter-
action space not evaluated in the original qPCR studies 
led us to investigate whether these markers are also mod-
ulated by vortioxetine. Thus, we performed a follow-up 
qPCR study as biological validation of the network analy-
sis. Adult rats received chronic vortioxetine at a range of 
doses with varying SERT and 5-HT receptor occupancies, 
and mRNA levels of various plasticity markers and recep-
tors were measured in the frontal cortex and hippocam-
pus and compared to the control treatment group. We 
found that the same biology was regulated in this model 
system. Arc, involved in synaptic and structural plasticity, 
was downregulated in response to 0.6 g/kg (0.42 ± 0.05, 
VOR vs. 1.00  ±  0.17, Ctrl) and 1.8  g/kg (0.28  ±  0.04, 
VOR, vs. 1.00  ±  0.17, Ctrl) vortioxetine in the frontal 
cortex and in response to 1.8 g/kg (0.64 ± 0.05, VOR vs. 
1.00 ± 0.13, Ctrl) vortioxetine in the hippocampus rela-
tive to control (Fig. 6a) (also see [27]). The transcription 
factor Fos was also downregulated following chronic 
0.6 g/kg (Cortex: 0.43 ± 0.06, VOR vs. 1.00 ± 0.15, Ctrl; 
Hippocampus: 0.53  ±  0.06, VOR vs. 1.00  ±  0.12, Ctrl) 
and 1.8 g/kg (Cortex: 0.25 ± 0.03, VOR vs. 1.00 ± 0.15, 
Table 3 Biomarkers significantly upregulated by  vortiox-
etine in rat frontal cortex (VEH vs. VOR)
Significance is determined relative to VEH (saline) treatment (n = 5 animals for 
VEH; n = 6 animals for VOR). Due to the lower sample size, significance was not 
achieved following correction for multiple testing and thus, significant targets 
before correction were determined. A total of 14 targets were significantly 
modulated in response to VOR treatment and used as inputs in the network 
analysis
Gene name Protein ID Un‑corrected p value <0.05
Cacng2 CCG2 0.0173
Cacng6 CCG6 0.0173
Cacng8 CCG8 0.0173
Grik4 GRIK4 0.0095
Grik5 GRIK5 0.0095
Grm1 GRM1 0.0095
Grm5 GRM5 0.0095
Grm7 GRM7 0.0095
Homer3 HOMER3 0.0095
Htr1b 5-HT1B 0.0173
Mtor MTOR 0.0317
Ppp1r9b Spinophilin/NEB2 0.0303
Prkca KPCA 0.0303
Syn3 SYN3 0.0317
Page 7 of 15Waller et al. BMC Neurosci  (2017) 18:56 
a
b
Both networks
Mouse network
Rat network
p-value for differential expression
Wilcoxon_p-value
0 0.05 0.10 1.00
0 1.00
Fig. 2 Mouse and rat networks mapped to human proteins. a Mouse network. The 5 significantly-regulated targets following correction for mul-
tiple testing were used to generate a protein–protein interaction network. The genes highlighted in green represent the 5 differentially-regulated 
mouse genes. p = 0.001652, Wilcoxon, enrichment of significantly-regulated biomarkers relative to vehicle-treated mice. b Rat network. The 14 
differentially-regulated genes before correction for multiple testing were used for the network analysis. The genes highlighted in green represent 
the 14 targets that showed significance following differential analysis. p = 0.00000642, Wilcoxon, enrichment of significantly-regulated targets in 
comparison to vehicle-treated rats. The scale indicates p values for significance of differential expression, ranging from green (p = 0) to dark red 
(p = 1)
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Ctrl; Hippocampus: 0.43  ±  0.05, VOR vs. 1.00  ±  0.12, 
Ctrl) vortioxetine treatment in the frontal cortex and hip-
pocampus (Fig. 6b) (also see [27]). Of the additional bio-
markers identified by the network analysis, Epn1 (Epsin 
1), associated with endocytic functions and actin remod-
eling, was upregulated in the frontal cortex by 0.22  g/
kg (1.41  ±  0.18, VOR vs. 1.00  ±  0.06, Ctrl) and 0.6  g/
kg (1.46 ± 0.13, VOR vs. 1.00 ± 0.06, Ctrl) vortioxetine 
treatment, and the neurodevelopmental and plasticity 
biomarker Sema4g (Semaphorin 4g) was also upregulated 
by 0.22 g/kg (1.27 ± 0.13, VOR vs. 1.00 ± 0.07, Ctrl) vor-
tioxetine treatment in the frontal cortex (Fig. 6c) (also see 
[27]).
Discussion
We have performed a retrospective cross-species net-
work analysis of distinct datasets and studies to deter-
mine whether common biological systems are modulated 
in response to vortioxetine treatment. We found sig-
nificant overlap between mouse and rat and reveal that 
vortioxetine regulates shared biological networks in two 
distinct animal models differing in species, sexes, brain 
regions, and treatment regimens. Moreover, a subse-
quent additional qPCR analysis revealed that the same 
biology is modulated in response to chronic vortioxe-
tine treatment of adult rats. This indicates that common 
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Fig. 3 Merged mouse and rat network (mapped to human proteins). The colored genes were used to build the analysis/network of protein–protein 
interaction partners. The squares with colored borders represent targets from the rat network, and colored circles indicate targets from the mouse 
network. The arrowheads indicate the common targets found in mouse and rat networks. p = 0.0000808, Wilcoxon, mouse data, enrichment of 
regulated biomarkers. p = 0.00000217, Wilcoxon, rat data, enrichment of regulated biomarkers. The scale denotes p values for significance of dif-
ferential expression, ranging from green (p = 0) to dark red (p = 1). Targets with colored borders represent the rat p value, and center colors indicate 
mouse p values. Gray represents targets in which no qPCR data were obtained
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biological mechanisms are regulated in response to vorti-
oxetine treatment.
The mRNA levels of targets modulated by vortioxetine 
treatment provide a link to the role of vortioxetine in 
improved pro-cognitive performance in preclinical and 
clinical studies. The immediate early genes (IEGs) ARC 
and FOS, markers of neuronal activation, are consistently 
modulated in response to vortioxetine treatment. ARC is 
a cytoskeletal protein involved in various forms of syn-
aptic plasticity, including LTP, long-term depression, and 
homeostatic plasticity, as well as morphological plasticity 
[29, 30]. Given the role of vortioxetine in enhancing LTP 
in  vitro in hippocampal slices [13] and increasing den-
dritic branching and dendritic spine density in vivo [14, 
Both networks
Mouse network
Rat network
Interactions of neurexins and neuroligins at synapses Activation of Ca2+-permeable Kainate receptors
mTOR signaling Cargo recognition for clathrin-mediated endocytosis
Fig. 4 Merged mouse and rat network (mapped to human proteins) and overlapping Reactome pathways. Genes are colored according to their 
Reactome pathway memberships (DLG4 is part of both ‘Interactions of neurexins and neuroligins at synapses’ and ‘Activation of  Ca2+-permeable 
Kainate receptors’ pathways). The most prevalent Reactome pathways are shown. The network includes 13 (equal to 22%) of the proteins from the 
‘Interactions of neurexins and neuroligins at synapses’ pathway, 6 (equal to 60%) of the proteins from the ‘Activation of  Ca2+-permeable Kainate 
receptors’ pathway, 8 (equal to 50%) of the proteins from the ‘mTOR signaling’ pathway, and 7 (equal to 7%) of the proteins from the ‘Cargo recogni-
tion for clathrin-mediated endocytosis’ pathway. Reactome pathway annotations were filtered to include only reviewed human proteins from 
UniProt and protein-pathway associations with the evidence code “traceable author statement” (TAS)
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a b
c d
Fig. 5 Protein complex analysis. a Complex 1544—the Arc pathway, synaptic plasticity-related, is regulated by vortioxetine treatment at the mRNA 
level. b Complex 85—transcriptional regulation, including FOS modulated by vortioxetine at the mRNA level. c Complex 163—endocytosis/neuro-
transmitter release pathways, including EPN1 that was upregulated in the qPCR study. d DLG4/PSD-95 network, including SEMA4G that was upreg-
ulated in the qPCR study. The connecting lines represent physical protein–protein interactions. The targets outlined in red indicate genes modulated 
in response to chronic vortioxetine treatment in adult rats. The scale indicates p values for significance of differential expression, ranging from green 
(p = 0) to dark red (p = 1). Targets with colored borders represent the rat p value, and center colors indicate mouse p values. Gray represents targets in 
which no qPCR data were obtained
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15], regulation of ARC by vortioxetine may contribute 
to these effects on synaptic and structural plasticity. The 
IEG FOS is also induced by neuronal activity and plays a 
role in induction of NMDA receptor-dependent LTP and 
in hippocampus-dependent spatial learning tasks [31]. 
Regulation of FOS expression by vortioxetine in the hip-
pocampus may also contribute to its effect on enhancing 
LTP and visuospatial learning in middle-aged mice [20].
a
b
c
Fig. 6 Vortioxetine significantly regulates biomarkers within the protein–protein interactome identified by the network analysis. qPCR analysis fol-
lowing chronic vortioxetine (VOR) administration at a range of doses reveals genes identified in the network analysis are significantly modulated by 
vortioxetine. a Plasticity-related targets. Arc is significantly downregulated in response to 0.6 and 1.8 g/kg VOR in the frontal cortex and in response 
to 1.8 g/kg VOR in the hippocampus. Cortex: *p = 0.021, 0.6 g/kg versus control (Ctrl); **p = 0.005, 1.8 g/kg versus Ctrl. Hippocampus: *p = 0.033, 
1.8 g/kg versus Ctrl. b Transcription factors. Fos is significantly downregulated in response to 0.6 and 1.8 g/kg VOR in the frontal cortex and hip-
pocampus. Cortex: *p = 0.034, 0.6 g/kg versus Ctrl; **p = 0.007, 1.8 g/kg versus Ctrl. Hippocampus: **p = 0.009, 0.6 g/kg versus Ctrl; **p = 0.004, 
1.8 g/kg versus Ctrl. c Endocytosis/actin remodeling and neurodevelopment/plasticity. Epn1 is significantly upregulated in response to 0.22 and 
0.6 g/kg VOR treatment in the frontal cortex. *p = 0.070, 0.22 g/kg versus Ctrl; **p = 0.001, 0.6 g/kg versus Ctrl. Sema4g is significantly upregulated 
following 0.22 g/kg vortioxetine treatment in the frontal cortex. *p = 0.040, 0.22 g/kg versus Ctrl. All values are represented as fold change relative 
to the control group and denoted as mean ± SEM. Statistical significance is defined as a FDR p value of p < 0.05. n = 12 animals per group
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The transcription of two biomarkers detected in the 
network analysis, EPN1 (Epsin 1) and SEMA4G (Sema-
phorin 4g) was confirmed by qPCR analysis to be upreg-
ulated by vortioxetine treatment (also see [27]). The 
adaptor protein EPN1 interacts with neurotransmitter 
re-uptake machinery in the presynaptic region and is 
involved in clathrin-mediated endocytosis and vesicle 
budding, both of which are actin-dependent events [32]. 
It also plays a role in transcriptional regulation and medi-
ates actin polymerization and assembly [33–36]. Regula-
tion of EPN1 expression by vortioxetine may influence 
its role in actin remodeling and in maintenance of den-
dritic spine structure [16]. Semaphorins have predomi-
nant roles in axon guidance and neurodevelopment, but 
are continually expressed into adulthood where they can 
mediate synapse stability and hippocampal plasticity [37, 
38]. SEMA4G interacts with the major postsynaptic scaf-
fold protein postsynaptic density 95 (PSD-95) [38], which 
links the NMDA receptor complex to downstream sign-
aling pathways. Thus, SEMA4G may function in refining 
postsynaptic specializations and modulating synaptogen-
esis and NMDA-mediated signal transduction pathways, 
processes relevant to vortioxetine’s role in plasticity and 
cognitive-enhancing performance.
The differential regulation of specific targets in mouse 
versus rat may be partly due to treatment-specific effects. 
Chronic vortioxetine was administered in middle-aged 
mice, which predominantly showed modulation of IEG 
expression, whereas adult rats, in which calcium chan-
nel and glutamate receptor expression was significantly 
regulated, were treated with acute vortioxetine. In line 
with these findings, chronic vortioxetine treatment in 
adult rats can promote cell-type specific regulation of 
c-fos protein expression in certain subregions of the hip-
pocampus (ongoing study, yet unpublished). Accord-
ingly, cell-type specific effects in response to vortioxetine 
treatment may be diluted in whole tissue preparations, 
and expression of these targets at the protein level may 
be regulated differently. However, the distinct targets 
in mouse versus rat likely converge on common down-
stream pathways. Glutamate receptor and calcium 
channel activity can modulate IEG expression as well as 
transcription of synaptic targets. Stimulation of metabo-
tropic glutamate receptors and subsequent elevated 
calcium responses lead to an increase in dendritic Arc 
levels, and this increase is abrogated by calcium channel 
blockers [39]. NMDAR hypofunction in mice deficient in 
serine racemase (SR), the enzyme that converts l-serine 
to the NMDAR coagonist d-serine, leads to reduced Arc 
expression in the hippocampus [40]. Conversely, acute 
d-cycloserine treatment to partially activate NMDARs at 
a dose corresponding to enhanced memory acquisition 
and consolidation promotes increased Arc protein lev-
els in the hippocampus [41]. In addition, calcium influx 
through voltage-sensitive calcium channels triggers 
CREB-mediated transcription of c-fos [42, 43]. Thus, the 
differentially-regulated targets in mouse versus rat may 
ultimately impact similar plasticity mechanisms.
Although sex-specific differences prevail in MDD and 
the antidepressant response [44–48], we find similar 
biological networks modulated in female mice and male 
rats following chronic and acute vortioxetine treatment, 
respectively. Neurosteroids induce profound effects on 
neuronal activity and memory. Estradiol augments LTP, 
elevates dendritic spine density in the hippocampus, 
and enhances cognitive performance in hippocampal-
dependent memory tasks [49–51]. Moreover, progester-
one metabolites target the inhibitory  GABAA receptor 
and can therefore influence cognitive function [52]. In 
addition, androgens maintain hippocampal-dependent 
plasticity and cognitive function [53]. Testosterone-
depleted rats exhibit elevated hippocampal CA3 mossy 
fiber LTP and branching [54], which may be compen-
sating for decreased CA1 spine synapses [53]. At the 
behavioral level, endogenous testosterone in the pre-
frontal cortex has been correlated with enhanced work-
ing and reference memory during spatial learning [55]. 
Furthermore, testosterone-derived steroids can have 
neuroprotective effects [56–58]. Neurosteroids can 
also act as positive modulators of NMDA receptors and 
increase NMDA receptor surface expression [59, 60]. 
Thus, analogous regulation of pathways in female and 
male rodents may be related to a certain extent to the 
effects of neurosteroids on synaptic plasticity and cog-
nitive processes.
Conclusions
A central goal has been to identify novel biomarkers that 
play a role in MDD and may predict treatment response 
in MDD. However, due to the heterogeneity of MDD 
and variations in response to different treatments across 
different patient populations, it is difficult to attribute a 
single gene as a predictor of treatment response. In addi-
tion, cognitive dysfunction is prevalent in MDD [61], 
and vortioxetine alleviates cognitive dysfunction in vari-
ous preclinical models [17–21] as well as in clinical stud-
ies [62–64]. We show here that vortioxetine consistently 
modulates the transcription of genes in synaptic plas-
ticity-related networks, and the same biological mecha-
nisms are engaged in distinct model systems, providing 
support for the neuroplasticity hypothesis of depres-
sion. Thus, the pro-cognitive characteristics of vortiox-
etine may be achieved by enhancing signaling in these 
networks.
Page 13 of 15Waller et al. BMC Neurosci  (2017) 18:56 
Abbreviations
MDD: major depressive disorder; AMPA: α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid; NMDA: N-methyl-d-aspartate; 5-HT: serotonin; VOR: 
vortioxetine; SERT: 5-HT transporter; LTP: long-term potentiation; SSRI: selec-
tive serotonin-reuptake inhibitor; Ct: comparative cycle threshold; RQ: relative 
expression; FDR: false discovery rate; EPN1: Epsin 1; SEMA4G: Semaphorin 4g; 
IEG: immediate early gene; PSD-95: postsynaptic density 95.
Authors’ contributions
JAW, SHN, YL, KGD, ALP, CS, and RW participated in research design. JAW, 
YL, KGD, JAT, AA, and BE performed animal dosing, sample prepartion, and 
conducted qPCR experiments. SHN and RW contributed new analytic tools, 
including network and protein-interaction analysis. JAW, SHN, YL, KGD, JAT, 
AA, BE, and RW performed data analysis. JAW, SHN, CS, and RW wrote or 
contributed to writing of the manuscript. All authors read and approved the 
final manuscript.
Author details
1 External Sourcing and Scientific Excellence, Lundbeck Research U.S.A., Para-
mus, NJ 07652, USA. 2 Intomics A/S, Diplomvej 377, 2800 Lyngby, Denmark. 
3 Translational Neuropsychiatry Unit, Aarhus University, 8240 Risskov, Denmark. 
4 In Vitro Biology, Lundbeck Research U.S.A., Paramus, NJ 07652, USA. 5 Center 
for Biological Sequence Analysis, Technical University of Denmark, 2800 Lyn-
gby, Denmark. 
Acknowledgements
This study was supported by H. Lundbeck A/S and Takeda Pharmaceutical 
Company, Ltd.
Competing interests
Jessica A. Waller, Yan Li, Joseph A. Tamm, Aicha Abdourahman, Alan L. Pehrson, 
and Connie Sánchez were full-time employees of Lundbeck Research U.S.A. at 
the time this study was performed.
Availability of data and materials
The datasets supporting the results and conclusions of this study are available 
from the corresponding author on reasonable request.
Additional files
Additional file 1: Table S1. Differential expression analysis of mouse 
hippocampal qPCR data. A panel of 73 biomarkers was examined in a 
chronic vortioxetine study in aged mice and subject to differential analysis 
for identification of significantly-regulated targets to generate protein–
protein interaction networks. Table S2. Differential expression analysis of 
rat frontal cortex qPCR data. A panel of 80 biomarkers was evaluated in an 
acute vortioxetine study in adult rats and subject to differential analysis for 
identification of differentially-regulated targets to build protein–protein 
interaction networks. Table S3. List of targets examined in OpenArray 
study. Gene expression levels of biomarkers related to transcriptional reg-
ulation, signal transduction, synaptic plasticity, neurotransmitter release, 
neurodevelopment, and degradation, and of receptors and channels were 
evaluated in a chronic vortioxetine study in adult rats. The targets outlined 
in red indicate additional genes identified in the network and pre-defined 
complex analyses.
Additional file 2: Figure S1. Merged mouse and rat network (mapped 
to human proteins) and summary of biological functions of each sub-
network. Biological functions were manually extracted from the Function 
and Gene Ontology fields of the UniProt protein entries. The genes with 
dark, bold borders were used to build the network of protein–protein inter-
action partners. Squares with bold borders represent upregulated targets 
from the rat network, and circles with bold borders indicate differentially-
regulated targets from the mouse network. The arrowheads indicate 
the common targets found in mouse and rat networks. This network of 
physically-interacting proteins containing clusters related to synaptic plas-
ticity, synaptic transmission, neurodevelopment, cell growth, metabolism, 
and apoptosis, was significantly modulated in both mouse and rat.
Ethics approval and consent to participate
 All animal procedures were in accordance with Lundbeck Research U.S.A. 
Institutional Animal Care and Use Committee and NIH federal guidelines.
Funding
This study was supported by H. Lundbeck A/S and Takeda Pharmaceutical 
Company, Ltd, and the funding sources did not contribute to study design, 
data collection, data analysis, or writing of the manuscript.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 1 April 2017   Accepted: 21 July 2017
References
 1. Thompson SM, Kallarackal AJ, Kvarta MD, Van Dyke AM, LeGates TA, Cai 
X. An excitatory synapse hypothesis of depression. Trends Neurosci. 
2015;38(5):279–94.
 2. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential 
therapeutic targets. Science. 2012;338(6103):68–72.
 3. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a conver-
gence of mechanisms. Neuropsychopharmacology. 2008;33(1):88–109.
 4. Serafini G. Neuroplasticity and major depression, the role of modern 
antidepressant drugs. World J Psychiatry. 2012;2(3):49–57.
 5. Kang HJ, Voleti B, Hajszan T, Rajkowska G, Stockmeier CA, Licznerski P, 
Lepack A, Majik MS, Jeong LS, Banasr M, et al. Decreased expression of 
synapse-related genes and loss of synapses in major depressive disorder. 
Nat Med. 2012;18(9):1413–7.
 6. Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC, 
Jurjus GJ, Dieter L, Duman RS. Altered expression of synapse and gluta-
mate related genes in post-mortem hippocampus of depressed subjects. 
Int J Neuropsychopharmacol. 2013;16(1):69–82.
 7. Yuen EY, Wei J, Liu W, Zhong P, Li X, Yan Z. Repeated stress causes cogni-
tive impairment by suppressing glutamate receptor expression and 
function in prefrontal cortex. Neuron. 2012;73(5):962–77.
 8. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neuro-
transmission as a strategy for treating depression and cognitive dysfunc-
tion. CNS Spectr. 2014;19:121–33.
 9. Cai X, Kallarackal AJ, Kvarta MD, Goluskin S, Gaylor K, Bailey AM, Lee HK, 
Huganir RL, Thompson SM. Local potentiation of excitatory synapses by 
serotonin and its alteration in rodent models of depression. Nat Neurosci. 
2013;16(4):464–72.
 10. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, 
Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, et al. Discovery of 
1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel 
multimodal compound for the treatment of major depressive disorder. J 
Med Chem. 2011;54(9):3206–21.
 11. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with 
multimodal activity: review of preclinical and clinical data. Pharmacol 
Ther. 2015;145:43–57.
 12. Riga MS, Sanchez C, Celada P, Artigas F. Involvement of 5-HT3 receptors 
in the action of vortioxetine in rat brain: focus on glutamatergic and 
GABAergic neurotransmission. Neuropharmacology. 2016;108:73–81.
 13. Dale E, Zhang H, Leiser SC, Xiao Y, Lu D, Yang CR, Plath N, Sanchez C. Vorti-
oxetine disinhibits pyramidal cell function and enhances synaptic plastic-
ity in the rat hippocampus. J Psychopharmacol. 2014;28(10):891–902.
 14. Guilloux JP, Mendez-David I, Pehrson A, Guiard BP, Reperant C, Orvoen S, 
Gardier AM, Hen R, Ebert B, Miller S, et al. Antidepressant and anxiolytic 
potential of the multimodal antidepressant vortioxetine (Lu AA21004) 
assessed by behavioural and neurogenesis outcomes in mice. Neurop-
harmacology. 2013;73:147–59.
 15. Chen F, du Jardin KG, Waller JA, Sanchez C, Nyengaard JR, Wegener G. 
Vortioxetine promotes early changes in dendritic morphology com-
pared to fluoxetine in rat hippocampus. Eur Neuropsychopharmacol. 
2015;26(2):234–45.
Page 14 of 15Waller et al. BMC Neurosci  (2017) 18:56 
 16. Waller JA, Chen F, Sanchez C. Vortioxetine promotes maturation of 
dendritic spines in vitro: a comparative study in hippocampal cultures. 
Neuropharmacology. 2016;103:143–54.
 17. du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dose-
dependently reverses 5-HT depletion-induced deficits in spatial working 
and object recognition memory: a potential role for 5-HT1A receptor 
agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol. 
2014;24(1):160–71.
 18. Mork A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, 
Gulinello M, Sanchez C. Vortioxetine (Lu AA21004), a novel multimodal 
antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 
2013;105:41–50.
 19. Wallace A, Pehrson AL, Sanchez C, Morilak DA. Vortioxetine restores 
reversal learning impaired by 5-HT depletion or chronic intermittent cold 
stress in rats. Int J Neuropsychopharmacol. 2014;17(10):1695–706.
 20. Li Y, Abdourahman A, Tamm JA, Pehrson AL, Sanchez C, Gulinello M. 
Reversal of age-associated cognitive deficits is accompanied by increased 
plasticity-related gene expression after chronic antidepressant adminis-
tration in middle-aged mice. Pharmacol Biochem Behav. 2015;135:70–82.
 21. Jensen JB, du Jardin KG, Song D, Budac D, Smagin G, Sanchez C, Pehrson 
AL. Vortioxetine, but not escitalopram or duloxetine, reverses memory 
impairment induced by central 5-HT depletion in rats: evidence 
for direct 5-HT receptor modulation. Eur Neuropsychopharmacol. 
2014;24(1):148–59.
 22. Koenigs M, Grafman J. The functional neuroanatomy of depression: 
distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav 
Brain Res. 2009;201(2):239–43.
 23. Sapolsky RM. Depression, antidepressants, and the shrinking hippocam-
pus. Proc Natl Acad Sci USA. 2001;98(22):12320–2.
 24. du Jardin KG, Wegener G, Elfving B. Single dose vortioxetine or ketamine 
but not fluoxetine increases expression of neuroplasticity genes in the rat 
prefrontal cortex. Eur Neuropsychopharmacol. 2013;23:S392.
 25. Elfving B, Bonefeld BE, Rosenberg R, Wegener G. Differential expression of 
synaptic vesicle proteins after repeated electroconvulsive seizures in rat 
frontal cortex and hippocampus. Synapse. 2008;62(9):662–70.
 26. Li T, Wernersson R, Hansen RB, Horn H, Mercer J, Slodkowicz G, Workman 
CT, Rigina O, Rapacki K, Staerfeldt HH, et al. A scored human protein–
protein interaction network to catalyze genomic interpretation. Nat 
Methods. 2017;14(1):61–4.
 27. Waller JA, Tamm JA, Abdourahman A, Pehrson AL, Li Y, Cajina M, Sanchez 
C. Chronic vortioxetine treatment in rodents modulates gene expression 
of neurodevelopmental and plasticity markers. Eur Neuropsychopharma-
col. 2017;27(2):192–203.
 28. Castillo-Davis CI, Hartl DL. GeneMerge—post-genomic analysis, data 
mining, and hypothesis testing. Bioinformatics. 2003;19(7):891–2.
 29. Bramham CR, Alme MN, Bittins M, Kuipers SD, Nair RR, Pai B, Panja D, 
Schubert M, Soule J, Tiron A, et al. The arc of synaptic memory. Exp Brain 
Res. 2010;200(2):125–40.
 30. Li Y, Pehrson AL, Waller JA, Dale E, Sanchez C, Gulinello M. A critical 
evaluation of the activity-regulated cytoskeleton-associated protein 
(Arc/Arg3.1)’s putative role in regulating dendritic plasticity, cognitive 
processes, and mood in animal models of depression. Front Neurosci. 
2015;9:279.
 31. Fleischmann A, Hvalby O, Jensen V, Strekalova T, Zacher C, Layer LE, Kvello 
A, Reschke M, Spanagel R, Sprengel R, et al. Impaired long-term memory 
and NR2A-type NMDA receptor-dependent synaptic plasticity in mice 
lacking c-Fos in the CNS. J Neurosci. 2003;23(27):9116–22.
 32. Mooren OL, Galletta BJ, Cooper JA. Roles for actin assembly in endocyto-
sis. Annu Rev Biochem. 2012;81:661–86.
 33. Wendland B. Epsins: adaptors in endocytosis? Nat Rev Mol Cell Biol. 
2002;3(12):971–7.
 34. De Camilli P, Chen H, Hyman J, Panepucci E, Bateman A, Brunger AT. The 
ENTH domain. FEBS Lett. 2002;513(1):11–8.
 35. Kay BK, Yamabhai M, Wendland B, Emr SD. Identification of a novel 
domain shared by putative components of the endocytic and cytoskel-
etal machinery. Protein Sci. 1999;8(2):435–8.
 36. Shen Q, He B, Lu N, Conradt B, Grant BD, Zhou Z. Phagocytic receptor 
signaling regulates clathrin and epsin-mediated cytoskeletal remod-
eling during apoptotic cell engulfment in C. elegans. Development. 
2013;140(15):3230–43.
 37. Bouzioukh F, Daoudal G, Falk J, Debanne D, Rougon G, Castellani V. 
Semaphorin3A regulates synaptic function of differentiated hippocampal 
neurons. Eur J Neurosci. 2006;23(9):2247–54.
 38. Burkhardt C, Muller M, Badde A, Garner CC, Gundelfinger ED, Puschel AW. 
Semaphorin 4B interacts with the post-synaptic density protein PSD-95/
SAP90 and is recruited to synapses through a C-terminal PDZ-binding 
motif. FEBS Lett. 2005;579(17):3821–8.
 39. Kumar V, Fahey PG, Jong YJ, Ramanan N, O’Malley KL. Activation of intra-
cellular metabotropic glutamate receptor 5 in striatal neurons leads to 
up-regulation of genes associated with sustained synaptic transmission 
including Arc/Arg3.1 protein. J Biol Chem. 2012;287(8):5412–25.
 40. Balu DT, Coyle JT. Chronic d-serine reverses arc expression and partially 
rescues dendritic abnormalities in a mouse model of NMDA receptor 
hypofunction. Neurochem Int. 2014;75:76–8.
 41. Donzis EJ, Thompson LT. D-cycloserine enhances both intrinsic excit-
ability of CA1 hippocampal neurons and expression of activity-regulated 
cytoskeletal (Arc) protein. Neurosci Lett. 2014;571:50–4.
 42. Sheng M, McFadden G, Greenberg ME. Membrane depolarization and 
calcium induce c-fos transcription via phosphorylation of transcription 
factor CREB. Neuron. 1990;4(4):571–82.
 43. Thompson MA, Ginty DD, Bonni A, Greenberg ME. L-type voltage-
sensitive  Ca2+ channel activation regulates c-fos transcription at multiple 
levels. J Biol Chem. 1995;270(9):4224–35.
 44. Burns MJ, Cain VA, Husaini BA. Depression, service utilization, and treat-
ment costs among Medicare elderly: gender differences. Home Health 
Care Serv Q. 2001;19(3):35–44.
 45. Kessler RC. Epidemiology of women and depression. J Affect Disord. 
2003;74(1):5–13.
 46. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, 
Joyce PR, Karam EG, Lee CK, Lellouch J, et al. Cross-national epidemiology 
of major depression and bipolar disorder. JAMA. 1996;276(4):293–9.
 47. Keers R, Aitchison KJ. Gender differences in antidepressant drug 
response. Int Rev Psychiatry. 2010;22(5):485–500.
 48. Sloan DM, Kornstein SG. Gender differences in depression and 
response to antidepressant treatment. Psychiatr Clin North Am. 
2003;26(3):581–94.
 49. Li C, Brake WG, Romeo RD, Dunlop JC, Gordon M, Buzescu R, Magarinos 
AM, Allen PB, Greengard P, Luine V, et al. Estrogen alters hippocampal 
dendritic spine shape and enhances synaptic protein immunore-
activity and spatial memory in female mice. Proc Natl Acad Sci USA. 
2004;101(7):2185–90.
 50. Spencer JL, Waters EM, Romeo RD, Wood GE, Milner TA, McEwen BS. 
Uncovering the mechanisms of estrogen effects on hippocampal func-
tion. Front Neuroendocrinol. 2008;29(2):219–37.
 51. Vierk R, Bayer J, Freitag S, Muhia M, Kutsche K, Wolbers T, Kneussel M, 
Sommer T, Rune GM. Structure–function–behavior relationship in 
estrogen-induced synaptic plasticity. Horm Behav. 2015;74:139–48.
 52. Birzniece V, Backstrom T, Johansson IM, Lindblad C, Lundgren P, Lofgren 
M, Olsson T, Ragagnin G, Taube M, Turkmen S, et al. Neuroactive steroid 
effects on cognitive functions with a focus on the serotonin and GABA 
systems. Brain Res Rev. 2006;51(2):212–39.
 53. MacLusky NJ, Hajszan T, Prange-Kiel J, Leranth C. Androgen modulation 
of hippocampal synaptic plasticity. Neuroscience. 2006;138(3):957–65.
 54. Skucas VA, Duffy AM, Harte-Hargrove LC, Magagna-Poveda A, Radman 
T, Chakraborty G, Schroeder CE, MacLusky NJ, Scharfman HE. Testos-
terone depletion in adult male rats increases mossy fiber transmis-
sion, LTP, and sprouting in area CA3 of hippocampus. J Neurosci. 
2013;33(6):2338–55.
 55. Schulz K, Korz V. Hippocampal testosterone relates to reference memory 
performance and synaptic plasticity in male rats. Front Behav Neurosci. 
2010;4:187.
 56. Barreto G, Veiga S, Azcoitia I, Garcia-Segura LM, Garcia-Ovejero D. Tes-
tosterone decreases reactive astroglia and reactive microglia after brain 
injury in male rats: role of its metabolites, oestradiol and dihydrotestoster-
one. Eur J Neurosci. 2007;25(10):3039–46.
 57. Frye CA, McCormick CM. Androgens are neuroprotective in the dentate 
gyrus of adrenalectomized female rats. Stress. 2000;3(3):185–94.
 58. Spritzer MD, Galea LA. Testosterone and dihydrotestosterone, but not 
estradiol, enhance survival of new hippocampal neurons in adult male 
rats. Dev Neurobiol. 2007;67(10):1321–33.
Page 15 of 15Waller et al. BMC Neurosci  (2017) 18:56 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 59. Kostakis E, Smith C, Jang MK, Martin SC, Richards KG, Russek SJ, Gibbs 
TT, Farb DH. The neuroactive steroid pregnenolone sulfate stimulates 
trafficking of functional N-methyl d-aspartate receptors to the cell surface 
via a noncanonical, G protein, and  Ca2+-dependent mechanism. Mol 
Pharmacol. 2013;84(2):261–74.
 60. Mifflin K, Benson C, Kerr B, Aricioglu F, Cetin M, Dursun S, Baker G. Involve-
ment of neuroactive steroids in pain, depression and anxiety. Mod Trends 
Pharmacopsychiatry. 2015;30:94–102.
 61. Lam RW, Kennedy SH, McLntyre RS, Khullar A. Cognitive dysfunction 
in major depressive disorder: effects on psychosocial functioning and 
implications for treatment. Can J Psychiatry. 2014;59(12):649–54.
 62. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-con-
trolled, duloxetine-referenced, fixed-dose study comparing the efficacy 
and safety of Lu AA21004 in elderly patients with major depressive 
disorder. Int Clin Psychopharmacol. 2012;27(4):215–23.
 63. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A rand-
omized, placebo-controlled, active-reference, double-blind, flexible-dose 
study of the efficacy of vortioxetine on cognitive function in major 
depressive disorder. Neuropsychopharmacology. 2015;40:2025–37.
 64. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, pla-
cebo-controlled study of vortioxetine on cognitive function in depressed 
adults. Int J Neuropsychopharmacol. 2014;17(10):1557–67.
